Telomir Pharmaceuticals Consolidates Global Rights to Telomir-Zn

Telomir Pharmaceuticals (NASDAQ: TELO) has successfully closed its acquisition of TELI Pharmaceuticals, Inc., a strategic move that consolidates global rights to its lead asset, Telomir-1 (Telomir-Zn). This acquisition eliminates previous geographic fragmentation, positioning Telomir as the sole global rights holder of the drug candidate. The transaction, which received shareholder approval in March, includes $1.0 million in funding at closing and up to an additional $4.0 million in milestone-based contributions tied to clinical development progress. With this consolidation, Telomir strengthens its position as it advances Telomir-Zn toward clinical trials, following a recent IND submission for the treatment of advanced and metastatic triple-negative breast cancer. The company plans to initiate a Phase 1/2 trial upon regulatory clearance while retaining flexibility for potential global partnerships.

Telomir Pharmaceuticals is a preclinical-stage biotechnology company focused on developing small-molecule therapeutics that target fundamental epigenetic and metabolic mechanisms implicated in cancer, aging, and degenerative disease. The lead program, Telomir-1 (Telomir-Zn), has demonstrated preclinical activity in modulating intracellular metal homeostasis, redox balance, epigenetically regulated gene expression, mitochondrial function, and genomic stability. The acquisition of TELI Pharmaceuticals not only consolidates intellectual property but also streamlines development efforts, potentially accelerating the path to market for this promising therapy.

For investors and industry watchers, this acquisition marks a pivotal step for Telomir Pharmaceuticals. By securing global rights and additional funding, the company is better positioned to advance its clinical pipeline. The news was disseminated through MissionIR, a specialized communications platform within the Dynamic Brand Portfolio @ IBN, which provides syndicated content and press release enhancement to boost visibility in the investment community. As Telomir moves toward clinical trials, the broader biotech sector will be watching closely for updates on Telomir-Zn's efficacy and safety profile.